Hepatitis B therapy

Nature Reviews Gastroenterology and Hepatology

Volumn 8, Issue 5, 2011, Pages 275-284

  Kwon, Hellan ^a   Lok, Anna S ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TELBIVUDINE; TENOFOVIR DISOPROXIL;

ACUTE LIVER FAILURE; ADD ON THERAPY; ANOREXIA; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; AUTOIMMUNE DISEASE; BONE DEMINERALIZATION; BONE MARROW SUPPRESSION; CLINICAL DECISION MAKING; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ACTIVITY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG PREFERENCE; DRUG SAFETY; DRUG TREATMENT FAILURE; EMOTIONAL DISORDER; FANCONI RENOTUBULAR SYNDROME; FATIGUE; FLU LIKE SYNDROME; HAIR LOSS; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TUBULE DISORDER; LACTIC ACIDOSIS; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; VIRUS CARRIER;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; NUCLEOSIDES; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 79955672370     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2011.33     Document Type: Review

References (84)

1. Yim, H. J. & Lok, A. S. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 43, S173-S181 (2006).
2. Fattovich, G., Bortolotti, F. & Donato, F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J. Hepatol. 48, 335-352 (2008).
3. Chu, C M., Hung., S. J., Lin, J., Tai, D. I. & Liaw, Y F. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am. J. Med. 116, 829-834 (2004). (Pubitemid 38721324)
4. Liaw, Y F. et al. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 84, 216-219 (1983). (Pubitemid 13224257)
5. Lok, A. S., Lai, C L., Wu, P C., Leung, E. K. & Lam, T. S. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 92, 1839-1843 (1987). (Pubitemid 17072230)
6. Chen, Y C., Chu, C. M. & Liaw, Y F. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology 51, 435-444 (2010).
7. Manno, M. et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 127, 756-763 (2004). (Pubitemid 39208409)
8. Chotiyaputta, W. & Lok, A. S. Hepatitis B virus variants. Nat Rev. Gastroenterol. Hepatol. 6, 453-462 (2009).
9. Iloeje, U. et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130, 678-686 (2006). (Pubitemid 43374518)
10. Chen, C. J. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295, 65-73 (2006).
11. van Zonneveld, M. et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39, 804-810 (2004). (Pubitemid 38337661)
12. Niederau, C. et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med. 334, 1422-1427 (1996). (Pubitemid 26157437)
13. Brunetto, M. R. et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J. Hepatol. 36, 263-270 (2002). (Pubitemid 34146434)
14. Papatheodoridis, G. V., Manesis, E. & Hadziyannis, S. J. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J. Hepatol. 34, 306-313 (2001). (Pubitemid 32176454)
15. Lampertico, P et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 37, 756-763 (2003). (Pubitemid 36397385)
16. Lau, G. K. et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352, 2682-2695 (2005). (Pubitemid 41007823)
17. Janssen, H. L. et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365, 123-129 (2005). (Pubitemid 40091801)
18. Chan, H. L. et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann. Intern. Med. 142, 240-250 (2005). (Pubitemid 40216241)
19. Buster, E. H. et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon a-2b. Gastroenterology 135, 459-467 (2008).
20. Marcellin, P et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351, 1206-1217 (2004). (Pubitemid 39296307)
21. Marcellin, P et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 136, 2169-2179.e1-4 (2009).
22. Perrillo, R. P et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 36, 186-194 (2002). (Pubitemid 34700777)
23. Wai, C T., Chu, C J., Hussain, M. & Lok, A. S. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C Hepatology 36, 1425-1430 (2002). (Pubitemid 35403533)
24. Buster, E. H. et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 137, 2002-2009 (2009).
25. Rijckborst, V et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 52, 454-461 (2010).
26. Moucari, R. et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 49, 1151-1157 (2009).
27. Hoofnagle, J. H., Di Bisceglie, A. M., Waggoner, J. G. & Park, Y Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 104, 1116-1121 (1993). (Pubitemid 23090765)
28. Buster, E. H. et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 46, 388-394 (2007). (Pubitemid 47344773)
29. Dienstag, J. L. et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341, 1256-1263 (1999). (Pubitemid 29489740)
30. Lai, C et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 339, 61-68 (1998). (Pubitemid 28304879)
31. Marcellin, P et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348, 808-816 (2003). (Pubitemid 36245757)
32. Chang, T. T. et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354, 1001-1010 (2006).
33. Marcellin, P et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 359, 2442-2455 (2008).
34. Lai, C. L. et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 357, 2576-2588 (2007).
35. Lee, H. W. et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology 51, 415-421 (2010).
36. Lok, A. S. et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125, 1714-1722 (2003). (Pubitemid 37500436)
37. Marcellin, P et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 48, 750-758 (2008).
38. Chang, T. T. et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51, 422-430 (2010).
39. Liaw, Y F. et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136, 486-495 (2009).
40. Heathcote, E. J. et al. Long term (4 year) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients (HBEAG+) with chronic hepatitis B (Study 103): preliminary analysis (abstract 477). Hepatology 52, 556A-557A (2010).
41. Dienstag, J. L. et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124, 105-117 (2003). (Pubitemid 36055344)
42. Hadziyannis, S. et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131, 1743-1751 (2006). (Pubitemid 44958517)
43. Chang, T. T. et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52, 886-893 (2010).
44. Tassopoulos, N. C et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 29, 889-896 (1999). (Pubitemid 29109606)
45. Hadziyannis, S. J. et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348, 800-807 (2003). (Pubitemid 36245756)
46. Lai, C. L. et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 354, 1011-1020 (2006).
47. Marcellin, P et al. Continued efficacy and safety through 4 years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-negative patients with chronic hepatitis B (study 102): preliminary analysis (abstract 476). Hepatology 52, 555A-556A (2010).
48. Lok, A. S. et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46, 254-265 (2007). (Pubitemid 47171942)
49. Tenney, D. J. et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49, 1503-1514 (2009).
50. Tenney, D. J. et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob. Agents Chemother. 48, 3498-3507 (2004). (Pubitemid 39129351)
51. Rapti, I., Dimou, E., Mitsoula, P. & Hadziyannis, S. J. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45, 307-313 (2007). (Pubitemid 46374587)
52. Yim, H. J. et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44, 703-712 (2006). (Pubitemid 44433727)
53. Wu, I. C et al. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology 51, 1185-1189 (2010).
54. Westland, C et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 125, 107-116 (2003). (Pubitemid 36799112)
55. Verhelst, D. et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am. J. Kidney Dis. 40, 1331-1333 (2002). (Pubitemid 35403147)
56. Purdy, J. B., Gafni, R. I., Reynolds, J. C., Zeichner, S. & Hazra, R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human mmunodeficiency virus. J. Pediatr. 152, 582-584 (2008). (Pubitemid 351381047)
57. Lange, C M. et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 50, 2001-2006 (2009).
58. Lok, A. S. & McMahon, B. J. Practice guidelines: chronic hepatitis B. Hepatology 45, 507-539 (2007).
59. Lok, A. S. & McMahon, B. J. Chronic hepatitis B: update 2009. American Association for the Study of Liver Diseases [online], http://www.aasld.org/practiceguidelines/Documents/ Bookmarked%20Practice%20Guidelines/ChronicHepBUpdate2009%208242009.pdf (2009).
60. Sorrell, M. F et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann. Intern. Med. 150, 104-110 (2009).
61. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol. 50, 227-242 (2009).
62. Liaw, Y F. et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int. 2, 263-283 (2008).
63. Fontana, R. J. et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy Gastroenterology 123, 719-727 (2002). (Pubitemid 34977078)
64. Yao, F Y, Terrault, N. A., Freise, C., Maslow, L. & Bass, N. M. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 34, 411-416 (2001). (Pubitemid 32702355)
65. Liaw, Y F. et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351, 1521-1531 (2004).
66. Hoofnagle, J. H. Reactivation of hepatitis B. Hepatology 49, S156-S165 (2009).
67. Loomba, R. et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann. Intern. Med. 148, 519-528 (2008). (Pubitemid 351665421)
68. Shi, Z., Yang, Y., Ma, L., Li, X. & Schreiber, A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet. Gynecol. 116, 147-159 (2010).
69. Han, G., Zhao, W., Cao, M., Jiang, H. & Pan, C A prospective and open-label study for the efficacy and safety of telbivudine(LTD) in pregnancy for the prevention of perinatal transmission of hepatitis B virus (HBV) to the infants (abstract 212). Hepatology 52, 427A-428A (2010).
70. Reijnders, J. G., Perquin, M. J., Zhang, N., Hansen, B. E. & Janssen, H. L. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 139, 491-498 (2010).
71. Sung, J. J. et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J. Hepatol. 48, 728-735 (2008).
72. Lai, C L. et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129, 528-536 (2005).
73. Berg, T. et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 139, 1207-1217 (2010).
74. Liaw, Y et al. Shorter duration and lower dose of Peginterferon Alfa-2A therapy results in inferior HBeAg seroconversion rates compared with the duration and dose of 48 weeks and 180 mG: neptune study (abstract 215). Hepatology 521, 429A-430A (2010).
75. Fan, X. et al. A head-to-head comparison of peginterferon α-2B treatment regimens in the treatment of Chinese and south-east Asian patients with HBeAg positive chronic hepatitis B. Hepatology 52, 386A (2010).
76. Lampertico, P et al. Safety and tolerability of extended (96 weeks) treatment with peginterferon alfa-2A [40KD] in genotype D patients with HBeAg-negative chronic hepatitis B. Hepatology 52, 387A (2010).
77. Hadziyannis, S. et al. Outcome of HBeAg-negative chronic hepatitis B (CHG) 5 years after discontinuation of long term adefovir dipivoxi (ADV) treatment (abstract 18). J. Hepatol. 50, S9 (2009).
78. Yuen, M. F. et al. Factors preceding hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34, 785-791 (2001).
79. Keeffe, E. B. et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin. Gastroenterol. Hepatol. 6, 1315-1341 (2008).
80. Tenney, D. J. et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49, 1503-1514 (2010).
81. Snow-Lampart, A. et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology doi:10.1002/hep.24078.
82. Lampertico, P et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133, 1445-1451 (2007). (Pubitemid 350047463)
83. van Bommel, F. et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51, 73-80 (2010).
84. Tan, J. et al. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J. Hepatol. 48, 391-398 (2008).